Updating results

462 results

Sort: Relevance | Date

Velmanase alfa for treating alpha-mannosidosis [ID800]

In development [GID-HST10010] Expected publication date: TBC

Highly specialised technologies guidance In development

Onasemnogene abeparvovec for treating spinal muscular atrophy type 1 [ID1473]

In development [GID-HST10026] Expected publication date: TBC

Highly specialised technologies guidance In development

Volanesorsen for treating familial chylomicronaemia syndrome [ID1326]

In development [GID-HST10015] Expected publication date: 27 May 2020

Highly specialised technologies guidance In development

Afamelanotide for treating erythropoietic protoporphyria [ID927]

In development [GID-HST10009] Expected publication date: TBC

Highly specialised technologies guidance In development

Lysosomal acid lipase deficiency - sebelipase alfa [ID737]

In development [GID-LYSOSOMALACIDLIPASEDEFICIENCYSEBELIPASEALFAID737] Expected publication date: TBC

Highly specialised technologies guidance In development

Human alpha1-proteinase inhibitor for treating emphysema ID856

In development [GID-HST10017] Expected publication date: TBC

Highly specialised technologies guidance In development

Elosulfase alfa for treating mucopolysaccharidosis type IVa (review of HST2) [ID1643]

In development [GID-HST10027] Expected publication date: 11 November 2020

Highly specialised technologies guidance In development

Metreleptin for treating lipodystrophy (ID861)

In development [GID-HST10011] Expected publication date: 13 January 2021

Highly specialised technologies guidance In development

Adults with complex needs: social work interventions including assessment, care management and support

In development [GID-NG10145] Expected publication date: 19 January 2022

NICE guideline In development

Advocacy services for adults with health and social care needs

In development [GID-NG10156] Expected publication date: 17 June 2022

NICE guideline In development

SpaceOAR hydrogel spacer for reducing rectal toxicity during radiotherapy for prostate cancer (Suspended – referred to technology appraisals)

In development [GID-MT526] Expected publication date: TBC

Medical technologies guidance In development

Danis Stent for acute oesophageal variceal bleeds

In development [GID-MT537] Expected publication date: 21 December 2020

Medical technologies guidance In development

The V.A.C. Veraflo Therapy system for infected wounds

In development [GID-MT543] Expected publication date: 06 October 2020

Medical technologies guidance In development

SEM Scanner 200 for pressure ulcer prevention

In development [GID-MT533] Expected publication date: 06 July 2020

Medical technologies guidance In development

DHT pilot: Lifelight First for monitoring vital signs

In development [GID-MT532] Expected publication date: TBC

Medical technologies guidance In development

DHT pilot: MyCOPD for self-management of chronic obstructive pulmonary disease (COPD)

In development [GID-MT531] Expected publication date: TBC

Medical technologies guidance In development

DHT pilot: Zio XT Service for detecting cardiac arrhythmias

In development [GID-MT534] Expected publication date: TBC

Medical technologies guidance In development

PneuX for preventing ventilator-associated pneumonia in intensive care

In development [GID-MT528] Expected publication date: 27 March 2020

Medical technologies guidance In development

Axonics sacral neuromodulation system for bladder control in people with symptoms of overactive bladder

In development [GID-MT530] Expected publication date: 01 June 2020

Medical technologies guidance In development

DHT pilot: DECODE decision support system for the identification of dementia

In development [GID-MT536] Expected publication date: TBC

Medical technologies guidance In development

Rezum for treating lower urinary tract symptoms secondary to benign prostatic hyperplasia

In development [GID-MT529] Expected publication date: 06 April 2020

Medical technologies guidance In development

Endo-Sponge for treating colorectal anastomotic leakage

In development [GID-MT539] Expected publication date: 01 September 2020

Medical technologies guidance In development

Leukomed Sorbact

In development [GID-MT541] Expected publication date: 22 December 2020

Medical technologies guidance In development

The MAGEC system for spinal lengthening in children with scoliosis

In development [GID-MT544] Expected publication date: 15 September 2020

Medical technologies guidance In development

Peezy Midstream for urine collection

In development [GID-MT538] Expected publication date: 26 January 2021

Medical technologies guidance In development

Crisaborole for treating mild to moderate atopic dermatitis in people aged 2 years and older (ID1195)

In development [GID-TA10435] Expected publication date: 03 June 2020

Technology appraisal guidance In development

Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (CDF Review TA600) ID1683

In development [GID-TA10537] Expected publication date: 12 August 2020

Technology appraisal guidance In development

Niraparib for maintenance treatment of platinum-sensitive ovarian, fallopian tube and peritoneal cancer after response to 1 course of platinum-based chemotherapy [ID1680]

In development [GID-TA10551] Expected publication date: 03 February 2021

Technology appraisal guidance In development

Nivolumab for previously treated locally advanced or metastatic non-squamous non-small-cell lung cancer (CDF review TA484) [ID1572]

In development [GID-TA10513] Expected publication date: 06 May 2020

Technology appraisal guidance In development

Nivolumab for previously treated squamous non-small-cell lung cancer (CDF Review TA483) [ID1559]

In development [GID-TA10516] Expected publication date: 06 May 2020

Technology appraisal guidance In development

Fenfluramine for treating Dravet syndrome [ID1109]

In development [GID-TA10373] Expected publication date: TBC

Technology appraisal guidance In development

Fedratinib for splenomegaly and symptoms in myelofibrosis [ID1501]

In development [GID-TA10406] Expected publication date: 24 March 2021

Technology appraisal guidance In development

Olaparib for previously treated hormone-relapsed metastatic prostate cancer [ID1640]

In development [GID-TA10584] Expected publication date: TBC

Technology appraisal guidance In development

Non-bisphosphonates for treating osteoporosis [ID901]

In development [GID-TA10072] Expected publication date: TBC

Technology appraisal guidance In development

Naldemedine for treating opioid-induced constipation ID1189

In development [GID-TA10291] Expected publication date: 05 June 2020

Technology appraisal guidance In development

Cabozantinib for treating advanced hepatocellular carcinoma after prior therapy [ID1243]

Technology appraisal [TA582] Published date: 24 May 2019

Technology appraisal guidance In development

Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma [ID1589]

In development [GID-TA10481] Expected publication date: 23 September 2020

Technology appraisal guidance In development

Vocimagene amiretrorepvec with extended-release 5-fluorocytosine for treating recurrent high-grade glioma [ID1425]

In development [GID-TA10542] Expected publication date: TBC

Technology appraisal guidance In development

TYRX Absorbable Antibacterial Envelope for preventing infection from cardiac implantable electronic devices [ID1440]

In development [GID-TA10370] Expected publication date: TBC

Technology appraisal guidance In development

Atezolizumab with nab-paclitaxel for treating PD L1-positive, triple-negative, advanced breast cancer [ID1522]

In development [GID-TA10433] Expected publication date: TBC

Technology appraisal guidance In development

Cositecan for treating platinum or taxane resistant advanced, mucinous, epithelial ovarian cancer [ID826]

In development [GID-TA10446] Expected publication date: TBC

Technology appraisal guidance In development

ATIR101 with haploidentical haematopoietic stem cell transplantation for haematological cancers [ID1093]

In development [GID-TA10445] Expected publication date: TBC

Technology appraisal guidance In development

Isatuximab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma [ID1477]

In development [GID-TA10448] Expected publication date: 05 August 2020

Technology appraisal guidance In development

Ublituximab with ibrutinib for previously treated chronic lymphocytic leukaemia [ID1476]

In development [GID-TA10447] Expected publication date: TBC

Technology appraisal guidance In development

Veliparib with carboplatin and paclitaxel for untreated epithelial ovarian, fallopian tube or primary peritoneal cancer ID1561

In development [GID-TA10442] Expected publication date: TBC

Technology appraisal guidance In development

Alpelisib in combination with fulvestrant for treating advanced hormone-receptor positive, HER2-negative, PIK3CA-positive breast cancer [ID1412]

In development [GID-TA10398] Expected publication date: 09 December 2020

Technology appraisal guidance In development

Pembrolizumab in combination with chemotherapy for neoadjuvant treatment of triple negative breast cancer [ID1500]

In development [GID-TA10399] Expected publication date: TBC

Technology appraisal guidance In development

Daratumumab in combination for untreated multiple myeloma when stem cell transplant is unsuitable ID1492

In development [GID-TA10441] Expected publication date: TBC

Technology appraisal guidance In development

Andexanet alfa for reversing anticoagulation [ID1101]

In development [GID-TA10440] Expected publication date: 10 June 2020

Technology appraisal guidance In development